The patient-specific nature of autologous cell therapies presents unique challenges that can best be addressed by a middle path between on-site and centralized manufacturing.

In recent decades, sensor-less cars that rely on human decision-making have evolved into self-driving taxis that arrive on demand. Beate Mueller-Tiemann, PhD, CTO of the global CDMO Cytiva, points to ...

Traditional microbial expression systems can be advanced through improved plasmid replication, target gene transcription, ...